Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.…
TD Cowen highlights catalysts for a 2027 Best Idea stock
Kiniksa Pharmaceuticals International (NASDAQ: KNSA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 366 employees.
The shares were at 93.89 USD on 20 November 2026, up 131.4% over 52 weeks. Its 52-week range is 37.02 USD to 99.31 USD: the price is 5.5% below the high and 153.6% above the low.
At a market capitalisation of 7.38B USD, it trades at 71.1 times trailing earnings and 45.9 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 190% for KNSA.
Kiniksa Pharmaceuticals International reports return on equity of 10.4%, an operating margin of 13.8% and revenue up 58.1% year over year.
It holds more cash than debt, a net cash position of 560.87M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 111.57 USD is 18.8% above the current price. The next earnings report is expected on 23 February 2027.